

**FORMATO EUROPEO  
PER IL CURRICULUM  
VITAE**



**INFORMAZIONI PERSONALI**

Nome

**CATALANO MARTINA**

Telefono

E-mail

Nazionalità

Data di nascita

**ESPERIENZA  
LAVORATIVA**

*Dal Dicembre 2017 a Dicembre 2022*

	<p>Medico in formazione specialistica in oncologia medica presso l'unità operativa di Oncologia medica (Prof. Antonuzzo) dell'università degli studi di Firenze</p> <p>Settembre 2017 Sostituzioni presso studio di Pediatra di Famiglia (Dr.ssa Dardano), Girifalco (CZ)</p> <p>Da Novembre 2016 al Maggio 2017 Borsista di ricerca per il progetto "Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions": presso l'Università Cattolica del Sacro Cuore di Roma</p> <p><i>Dal Maggio 2015 a Luglio 2016</i> Medico interno presso l'unità operativa di Oncologia Pediatrica (Prof. Ruggiero) dell'Università Cattolica del Sacro Cuore</p> <p><i>Dal Maggio 2014 a Aprile 2015</i> Medico interno presso l'unità operativa di Medicina Interna (Dott.Serricchio) dell'Università Cattolica del Sacro Cuore, Roma"</p>
--	---

<p><b>ISTRUZIONE E FORMAZIONE</b></p>	<p>Dicembre 2017-Dicembre 2022 Università di Firenze Diploma di specializzazione in Oncologia medica conseguito con 70/70 e Lode</p> <p>Settembre 2020-Settembre 2021 Campus in Oncologia: la gestione del dolore nella cronicizzazione della malattia</p> <p>Agosto 2020 Master di I livello in immuno-oncologia NIBIT</p> <p>Ottobre 2010-Luglio 2016 Università Cattolica del Sacro Cuore di Roma Laurea Specialistica in Medicina e Chirurgia</p> <p>Settembre 2005-Giugno 2010 Diploma di Maturità Scientifica Liceo Scientifico "Ettore Majorana", Girifalco (CZ)</p>
---------------------------------------	---

**CAPACITÀ E COMPETENZE  
PERSONALI**

MADRELINGUA

**ITALIANO**

ALTRE LINGUA

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione  
orale

**INGLESE**

**FRANCESE**

Buono

Buono

Buono

Elementare

Buono

Elementare

CAPACITÀ E COMPETENZE  
TECNICHE

CONOSCENZA DEI SEGUENTI PROGRAMMI:

WINDOWS, MICROSOFT WORD, EXCEL, POWERPOINT, INTERNET  
Patente Europea per Computer (ECDL)

CAPACITÀ E COMPETENZE  
ARTISTICHE

PATENTE O PATENTI

Patente di guida, categoria B

## Attività Scientifica

### **Pubblicazioni su riviste scientifiche**

1. Ruggiero A, Rizzo D, **Catalano M**, Attinà G, Riccardi R. Hypersensitivity to Carboplatin in Children with Malignancy. *Front Pharmacol.* 2017 Apr 12;8:201. **IF: 3.831** doi:10.3389/fphar.2017.00201.
2. Ruggiero A, Rizzo D, **Catalano M**, Maurizi P, Mastrangelo S, Attinà G, Riccardi R. Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions. *Front Pharmacol.* 2017 Apr 7;8:179. **IF: 3.831** doi:10.3389/fphar.2017.00179.
3. Ruggiero A, Rizzo D, **Catalano M**, Coccia P, Triarico S, Attinà G. Acute Chemotherapy-Induced Nausea and Vomiting in Children with Cancer: Still Waiting for a Common Consensus on Treatment. *J Med Int Res*, 2018 Jun **IF 1.39** doi: 10.1177/0300060518765324
4. **Catalano, M.**, Rizzo, D., Coccia, P., Maurizi, P., Nanni, L., Ruggiero, A. Can partial splenectomy preserve humoral immunity in pediatric patients? Risks and benefits of partial splenectomy. *Signa Vitae*, 2018, 14(1), pp. 17–19 **IF:0** doi: 10.22514/SV141.052018.2
5. Ruggiero, A., Pocino, K., **Catalano, M.**, Maurizi, P., D'ambra, M., Rizzo, D., Triarico, S., Attinà, G., Mastrangelo, S., Capoluongo, E.D. Serum biomarkers for sepsis in children with febrile neutropenia and cancer. *Journal of Biological Regulators and Homeostatic Agents*, 2019, 33(3), pp. 999–100 **IF 1.506**
6. **Catalano, M.**, Roviello, G., Conca, R., D'angelo, A., Palmieri, V.E., Panella, B., Petrioli, R., Ianza, A., Nobili, S., Mini, E., Ramello, M. Clinical outcomes and safety of patients treated with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: The napa study. *Current Cancer Drug Targets*, Volume 20, Issue 11, 2020, Pages 887-895. **IF: 2.92** doi: 10.2174/1568009620999200918122426
7. **Catalano, M.**, Conca, R., Petrioli, R., Ramello, M., Roviello, G. Folfox vs folfiri as second-line of therapy after progression to gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer. *Cancer Management and Research* Volume 12, 2020, Pages 10271-10278. **IF: 3.64** doi: 10.2147/CMAR.S267393
8. Lavacchi, D., Fancelli, S., Michelet, M.R.G., **Catalano, M.**, Roviello, G. REBECA trial: A new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer. *Translational Cancer Research* Volume 9, Issue 2, 1 February 2020, Pages 402-404. **IF: 0.7** doi: 10.21037/tcr.2019.12.83
9. Roviello, G., **Catalano, M.**, Nobili, S., Santi, R., Mini, E., Nesi, G. Focus on biochemical and clinical predictors of response to immune checkpoint inhibitors in metastatic urothelial carcinoma: Where do we stand? *International Journal of Molecular Sciences* Volume 21, Issue 21, 1 November 2020, Article number 7935, Pages 1-14. **IF: 4.556**doi: 10.3390/ijms21217935
10. Roviello, G., Ramello, M., **Catalano, M.**, D'Angelo, A., Conca, R., Gasperoni, S., Dreoni, Lc, Petrioli, R., Ianza, A., Nobili, S., Aieta, M., Mini, E. Association between neutropenia and survival to nab-

paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. *Scientific Reports* Volume 10, Issue 1, 1 December 2020, Article number 19281. **IF: 4.13** doi: 10.1038/s41598-020-76465-9 PubMed ID: 33159172

11. Roviello G., Aprile G., D'Angelo A., Iannone L.F., Roviello F., Polom K., Mini E., **Catalano M.** Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: where do we stand? *Gastric Cancer*, March 2021. **IF: 7.701**
12. Tartarone A., Lapadula V., Di Micco C., Rossi, G., Ottanelli C., Marini A., Giorgione R., Ferrari K., **Catalano M.**, Voltolini L, Mini E., Roviello G. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer. *Frontiers in Oncology* 11, May 2021. **IF: 6.244** doi: 10.3389/fonc.2021.632256.
13. Roviello G., **Catalano M.**, D'Angelo A., Palmieri V.E. Second line of treatment for HER2 positive gastric cancer: an evolving issue. *Rep Pract Oncol Radiother.* Apr 2021; 26(2): 316–317. **IF: 1.44** doi: 10.5603/RPOR.a2021.0024
14. **Catalano M.**, Aprile G., Ramallo M., Conca R., Petrolini R., Roviello G. Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. *Journal of Clinical Medicine* 10(9), Apr 2021. **FI: 4.964** doi: 10.3390/jcm10091846
15. **Catalano M.**, Campani C., Marra F., Vannini G., Mini E., Roviello G. Lenvatinib: Established and Promising Drug for the treatment of Advanced Hepatocellular Carcinoma. *Expert Review of Clinical Pharmacology.* Expert Review of Clinical Pharmacology, 2021, 14(11), pp. 1353–1365 **IF: 4.108**
16. Roviello, G., **Catalano, M.**, Santi, R., Palmieri, V.E., Vannini, G., Galli, I.C., Buttitta, E., Villari, D., Rossi, V., Nesi, G. Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives. *Cancers*, 2021, 13(17), 4411 **IF: 6.102**
17. Inno A, Roviello G, Ghidini A, Luciani A, **Catalano M**, Gori S, Petrelli F. Rechallenge of immune checkpoint inhibitors: a systematic review and meta-analysis. *Critical Reviews in Oncology/Hematology*, 2021, 165, 103434 **IF: 6.32**
18. Kaźmierczak-Siedlecka K, Roviello G, **Catalano M** and Połom K. Gut Microbiota Modulation in the Context of Immune-Related Aspects of *Lactobacillus* spp. and *Bifidobacterium* spp. in Gastrointestinal Cancers. *Nutrients*, 2021, 13(8), 2674 **IF: 6.43**
19. **Catalano, M.**, Marini, A., Ferrari, K., Voltolini, L., Cianchi, F., Comin, C.E., Castiglione, F., Roviello, G., Mini, E. Gastric and colonic metastasis from NSCLC A very unusual case report. *Medicine (United States)*, 2022, 101(2), pp. E28249 **IF: 1.817**
20. Roviello, G., Iannone, L.F., Bersanelli, M., Mini, E., **Catalano, M.** The gut microbiome and efficacy of cancer immunotherapy. *Pharmacology and Therapeutics*, 2022, 231, 107973 **IF: 12.95**
21. Roviello, G., Lavacchi, D., Antonuzzo, L., **Catalano, M.**, Mini, E. Liquid biopsy in colorectal cancer: No longer young, but not yet old. *World Journal of Gastroenterology*, 2022, 28(15), pp. 1503–1507 **IF: 5.74**
22. Palmieri, V.E., Roviello, G., **Catalano, M.**, D'Angelo, A., Vannini, G., Buttitta, E., Mini, E. Immune checkpoint inhibitor-induced

neurologic toxicity: a case report and literature review. *Immunotherapy*, 2022, 14(7), pp. 505– 510 **IF: 4.196**

23. Roviello, G., **Catalano, M.**, Iannone, L.F., Marano, L., Brugia, M., Rossi, G., Aprile, G., Antonuzzo, L. Current status and future perspectives in HER2 positive advanced gastric cancer. *Clinical and Translational Oncology*, 2022, 24(6), pp. 981–996 **IF: 3.405**
24. K Kaźmierczak-Siedlecka, A Daca, G Roviello, **M Catalano**, K Polom. Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known? *Gastric Cancer*. 2022; 25(1): 1–10. Published online 2021 Nov 6. **IF: 7.701** doi: 10.1007/s10120-021-01260-y
25. N Sobhani, B Scaggiante, R Morris, D Chai, **M Catalano**, DR Tardiel-Cyril, P Neeli, G Roviello, G Mondani, Y Li. Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. *Cancer Treatment Reviews*, 2022 Sep; 109: 102429. Published online 2022 Jun 22. **IF 6.024** doi: 10.1016/j.ctrv.2022.102429 102429
26. **M Catalano**, G Aprile, R Conca, R Petrioli, M Ramello, G Roviello. The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer. *Scientific reports*, 2022 May, 12 (1), 1-7 **IF: 4.379**
27. **M Catalano**, M Ramello, R Conca, G Aprile, R Petrioli, G Roviello. Risk factors for nab-paclitaxel and gemcitabine induced peripheral neuropathy in patients with pancreatic cancer. *Oncology*, 2022 Jul; 100 (7) **IF 4.33**
28. G Roviello, G Aprile, **M Catalano**, M Ramello, R Conca, R Petrioli. Capecitabine as second-line treatment for older patients with pancreatic cancer. *Current Pharmaceutical Biotechnology*, March 2022;23(15):1788-1791.**IF:2.83**  
doi:10.2174/1389201023666220307090450.
29. G Roviello, **M Catalano**, A D'Angelo, VE Palmieri. Second line of treatment for HER2 positive gastric cancer: anevolving issue. *reports of Practical oncology and radiotherapy* 26 (2), 316-317 **IF:1.44**
30. G Roviello, M Catalano, R Santi, M Santoni, IC Galli, A Amorosi, W Polom, U De Giorgi, G Nesi. Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: from the Beginning to the Latest Developments. *Frontiers in Oncology*, 22 July 2022. **IF:6.224** doi.org/10.3389/fonc.2022.912699
31. G Roviello, P Spatafora, F Sessa, C Bisegna, **M Catalano**, A Liaci, L Verdelli, E Illiano, I Camilla Galli, B Detti, G Nesi, G Vignolini, D Villari. Antiangiogenic drugs as chemosensitizer in renal cell cancer. *Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy*, 79-84
32. F Sessa, P Spatafora, G Roviello, C Bisegna, **M Catalano**, A Liaci, L Verdelli, E Illiano, I Camilla Galli, B Detti, G Nesi, G Vignolini, D Villari Antiangiogenic drugs as chemosensitizer in genitourinary cancer. *Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy*, 85-92
33. Becattini L, Saieva C, Doni L, Roviello G, Spatafora P, **Catalano M**, Sessa F, Galli IC, Bisegna C, Conte FL, Zaccaro C, Snati R, Nesi G, Villari D. Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity Following Chemotherapy. *Medicina*, July 2022, 58(7):886, **IF 0.653** doi:10.3390/medicina58070886
34. Roviello G., **Catalano M.**, Ottanelli C., Giorgione R., Rossi V.,

Gambale E., Casadei C., De Giorgi U., Antonuzzo L. Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. October 2022, *Medical Oncology* 39(10), **IF: 3.064** doi:10.1007/s12032-022-01739-3

35. Roviello G, **Catalano M**, De Giorgi U, Maruzzo M, Buti S, Gambale E, Procopio G, Ottanelli C, Caliman E, Isella L, Sepe P, Brighi N, Santoni M, Galli L, Conca R, Doni L, Antonuzzo L. Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors. *Front Oncol.* 2022 Aug 16;12:918413. **IF: 6.224** doi: 10.3389/fonc.2022.918413.
36. D'Angelo A, Chapman R, Sirico M, Sobhani N, **Catalano M**, Mini E, Roviello G. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next. *Cancer Chemother Pharmacol.* 2022 Sep;90(3):191-205. **IF:6.57** doi: 10.1007/s00280-022-04459-7.
37. Roviello G, **Catalano M**, Winchler C, De Gennaro Aquino I, Papa F, Buttitta E, Rossi G & Antonuzzo L Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy *Journal of Gastrointestinal Cancer* (2022). **IF:1.54** doi.org/10.1007/s12029-022-00865-5
38. **Catalano M**, De Giorgi U, Maruzzo M, Bimbatti D, Buti S, Mazzaschi G, Procopio G, Santoni M, Galli L, Conca R, Doni L, Antonuzzo L and Roviello G. Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma. *Biomedicines* 2022,10(10),2444; **IF:5.612** doi.org/10.3390/biomedicines10102444
39. Lepri G, **Catalano M**, Bellando-Randone S, Pillozzi S, Giommoni E, Giorgione R, Botteri C, Matucci-Cerinic M, Antonuzzo L & Guiducci S. Systemic Sclerosis Association with Malignancy. *Clinical Reviews in Allergy & Immunology* (2022). **IF:10. 89**
40. **Catalano M**, Nesi G, Roviello G. Immune combinations and complete response: a new hope for metastatic renal cell carcinoma. *Reports of Practical Oncology and Radiotherapy.* November 2022. DOI: 10.5603/RPOR.a2022.0119 **IF: 2.2**
41. Roviello G, **Catalano M**. Editorial: Microbiota and metabolites in cancer immunotherapy. *Frontiers in Oncology* 12:1093941. December 2022. DOI: 10.3389/fonc.2022.1093941 **IF 6.244**
42. Martina Catalano M, Shabani S, Venturini J, Ottanelli C, Voltolini L, Roviello G. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. *Cancers* 14(24):6145, December 2022. DOI: 10.3390/cancers14246145 **IF: 6.32**
43. Catalano M, Iannone L.F, Cosso F, Generali D, Mini E, Roviello G. Combining Inhibition of Immune Checkpoints and PARP: Rationale and Perspectives in Cancer Treatment. *Expert Opinion on Therapeutic Targets*, December 2022. DOI: 10.1080/14728222.2022.2158813. **IF: 6.902**
44. **M Catalano**, G Roviello, IC Galli, R Santi, G Nesi. Immune checkpoint inhibitor induced nephrotoxicity: an ongoing challenge. *Frontiers in Medicine* 9, 3773 December 2022. DOI: 10.3389/fmed.2022.1014257. **IF:5.05**
45. **M Catalano**, G Roviello, R Santi, D Villari, P Spatafora, IC Galli, F Sessa, FL Conte, E Mini, T Cai, G Nesi. Inflammation in Urological Malignancies: The Silent Killer. *International Journal of Molecular*

	Sciences. January 2023, 24(1):866. DOI: 10.3390/ijms24010866. <b>IF 6.20</b>
<b>Abstract congressi</b>	<p>XXI congresso Nazionale AIOM Long survival in patient with trabectedin and PLD: experience of a single center. Vannili L, Villanucci A, Ottanelli C, Catalano M, Giorgione R, Roviello G, Amunni G, Mini E.</p> <p>XXII congresso Nazionale AIOM Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Martina Catalano, Giandomenico Roviello, Monica Ramello, Alberto D'Angelo, Raffaele Conca, Silvia Gasperoni, Lorenzo Dreoni, Roberto Petrioli, Anna Ianza, Stefania Nobili, Michele Aieta, Enrico Mini.</p> <p>ASCO 2021 Gasperoni S., Papi L., Castiglione F., Gensini F., Sestini R., Messerini L., Bartoli C., Nozzoli F., Dimarino M., Cianchi F., Taddei A., Ferrara A., Calistri M., Bencini L., Perna F., Catalano M., Giorgione R., Winchler C., Venturi G., Mini E. Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epithelial tumors. Journal of Clinical Oncology 39 (15_suppl), e23520-e23520</p>
<b>Libri</b>	<p><i>-Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy: Elsevier</i> Antiangiogenic drugs as chemosensitizer in renal cell cancer (chapter 4) Antiangiogenic drugs as chemosensitizer in genitourinary cancer (chapter 5)</p>
<b>Revisore su invito per le seguenti riviste scientifiche</b>	<p>Frontiers in Immunology British Journal of Management Cancer treatment and Research Communication Cancers</p>
<b>Premi e Borse</b>	<p>Premio di Laurea (Luglio 2016), Università Cattolica del Sacro Cuore</p> <p>Borsa di studio (Nov 2016-Mag 2017) per il progetto "Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions": presso l'Università Cattolica del Sacro Cuore di Roma</p>
<b>Società Scientifiche</b>	<ul style="list-style-type: none"> <li>• Membro European Society for Medical Oncology (ESMO)</li> <li>• Membro Associazione Italiana Oncologia Medica (AIOM)</li> <li>• Membro Meet-URO Italian Network for Research in Urologic Oncology</li> <li>• Membro Gruppo Oncologico Italiano di Ricerca (GOIRC)</li> </ul>



*La sottoscritta Dott.ssa Catalano Martina dichiara che tutto quanto sopra citato corrisponde a verità ai sensi delle norme in materia di dichiarazioni sostitutive di cui agli artt.46 e seguenti del D.P.R. 445/2000. Ai sensi della legge 675/96, autorizza al trattamento dei dati personali contenuti nel presente Curriculum Vitae.*